UK follicular lymphoma patients set to get non-chemotherapy therapy as NICE backs Revlimid combo
That was fast!
UK’s cost-effectiveness agency NICE has endorsed the use of Celgene’s (now Bristol-Myers’) blockbuster cancer therapy Revlimid for patients with follicular lymphoma who have undergone previous treatment, about two months after the drug in combination with Roche’s MabThera secured approval from the EU regulator.
In contrast, NICE backed Revlimid as the first line of defense in certain patients with multiple myeloma about four years after European approval was sanctioned.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.